1. HASBROUCK HEIGHTS, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to provide an update on the Company's progress with its BPH treatment product Fexapotide Triflutate.

    The Company announced today that all Company tasks have been completed and documented and that the upcoming filing process in that regard has proceeded fully as planned. The Company is satisfied that it has fulfilled all of its required tasks and mandates at this point. The date of filing has been extended in a minor way mainly due to the need for certain forms and facility documents from third party vendors and contractors that are routinely required. Management assures Nymox shareholders that there are no…

    HASBROUCK HEIGHTS, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to provide an update on the Company's progress with its BPH treatment product Fexapotide Triflutate.

    The Company announced today that all Company tasks have been completed and documented and that the upcoming filing process in that regard has proceeded fully as planned. The Company is satisfied that it has fulfilled all of its required tasks and mandates at this point. The date of filing has been extended in a minor way mainly due to the need for certain forms and facility documents from third party vendors and contractors that are routinely required. Management assures Nymox shareholders that there are no material or unfamiliar elements unaccounted for in this update.

    Nymox is pleased to report that it has filed with regulatory bodies for brand names for Fexapotide. The Company has been formally informed by the authorities in more than one of the major jurisdictions that the proposed marketing trade names that were filed by the Company would be acceptable. Those acceptances are always subject to the outcomes of the filing processes.

    Nymox is also pleased to report updates on the acceptance and issuance of several new patents that will bolster the intellectual property protections for the new drug. These are from many different jurisdictions and provide increasing protection for the Company's assets.

    Dr Paul Averback, Nymox CEO said, "We are extremely pleased with the results of our long-haul labors and we expect to keep our supporters thoroughly informed, as much as we can. We obviously cannot speak for third party collaborators with whom we work except to say that we have nothing but good things to say about the commitment to quality which exists with our vendors and associates. The last few steps of documentation from the outside are not under our control. However, we expect the filing to occur soon and without major delay. The Company will report to shareholders within 30 days with all the information at hand."

    About Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH), Fexapotide Triflutate (FT), has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2020, and its Quarterly Reports.

    For Further Information Contact:

    Randall Lanham        

    Nymox Pharmaceutical Corporation

    1-800-93NYMOX

    www.nymox.com 



    Primary Logo

    View Full Article Hide Full Article
  2. HASBROUCK HEIGHTS, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before 15 September 2021.

    CEO Dr. Paul Averback said, "The Company will file on or before September 15. We hope but cannot be certain that the date may be before September. Company management will communicate updates where appropriate."

    About Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population…

    HASBROUCK HEIGHTS, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before 15 September 2021.

    CEO Dr. Paul Averback said, "The Company will file on or before September 15. We hope but cannot be certain that the date may be before September. Company management will communicate updates where appropriate."

    About Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH), Fexapotide Triflutate (FT), has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program.

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2020, and its Quarterly Reports.

    For Further Information Contact:

    Randall Lanham        

    Nymox Pharmaceutical Corporation

    1-800-93NYMOX

    www.nymox.com



    Primary Logo

    View Full Article Hide Full Article
  3. HASBROUCK HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") today announced it has entered into a definitive agreement with institutional investors in a private placement of 3,669,724 shares of common stock and warrants to purchase 1,834,862 shares of common stock at a combined purchase price of $2.18 per share for gross proceeds of approximately $8,000,000 before deducting fees and other estimated offering expenses. The warrants will have an exercise price of $2.50 per share, will be immediately exercisable and will expire five years from the date of issuance.

    The Company expects to use the net proceeds from the private placement for working capital and other general corporate…

    HASBROUCK HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") today announced it has entered into a definitive agreement with institutional investors in a private placement of 3,669,724 shares of common stock and warrants to purchase 1,834,862 shares of common stock at a combined purchase price of $2.18 per share for gross proceeds of approximately $8,000,000 before deducting fees and other estimated offering expenses. The warrants will have an exercise price of $2.50 per share, will be immediately exercisable and will expire five years from the date of issuance.

    The Company expects to use the net proceeds from the private placement for working capital and other general corporate purposes. The private placement is expected to close on or about April 30, 2021, subject to the satisfaction of customary closing conditions.

    A.G.P./Alliance Global Partners is acting as sole placement agent for the private placement.

    The private placement is being made pursuant to the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D as promulgated by the United States Securities and Exchange Commission (the "SEC") and the securities being sold in the private placement may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement on Form F-3 with the SEC covering the resale of the shares of common stock, as well as the shares of common stock issuable upon exercise of the warrants, issued in the private placement.

    This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

    About Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH), Fexapotide Triflutate (FT), has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2020, and its Quarterly Reports.

    For Further Information Contact:

    Erik Danielsen

    Nymox Pharmaceutical Corporation

    1-800-93NYMOX

    www.nymox.com



    Primary Logo

    View Full Article Hide Full Article
  4. HASBROUCK HEIGHTS, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to provide the latest update on the Company's regulatory filing preparation activities. The Company expects to file for approval for its first in class BPH treatment Fexapotide Triflutate, during the summer of this year. Management will provide a firm exact date for the filing in a subsequent disclosure. This communication of the exact date for the filing will be announced by the Company within the next 6 weeks. If there are any unexpected events that delay that announcement, the Company will provide immediate relevant updates.

    Paul Averback MD, CEO of Nymox, said, "We are very pleased to be able to provide a clear guidance…

    HASBROUCK HEIGHTS, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to provide the latest update on the Company's regulatory filing preparation activities. The Company expects to file for approval for its first in class BPH treatment Fexapotide Triflutate, during the summer of this year. Management will provide a firm exact date for the filing in a subsequent disclosure. This communication of the exact date for the filing will be announced by the Company within the next 6 weeks. If there are any unexpected events that delay that announcement, the Company will provide immediate relevant updates.

    Paul Averback MD, CEO of Nymox, said, "We are very pleased to be able to provide a clear guidance on dates at the above noted schedule within the next 6 weeks. We are grateful to our strong supporters who have understood that the process is not always conducive to fully predictable timelines. At this point however we are confident that we will be providing very specific details in that regard in the near future. Our product is capable of producing major improvements in men's health and it is remarkably safe and convenient to administer. We are working diligently toward the goal of making it available to men throughout the world."

    Dr. Averback added, "The last major drug innovations for BPH (alpha blockers and 5-ARIs) were first introduced over 30 years ago. If our work was an easy task, others would have accomplished this decades ago."

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2020, and its Quarterly Reports.

    For Further Information Contact:

    Erik Danielsen        

    Nymox Pharmaceutical Corporation

    1-800-93NYMOX

    www.nymox.com



    Primary Logo

    View Full Article Hide Full Article
  5. HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications.

    Unavoidable delays have been incurred in this project mainly due to the very long-term data, the standard requirements for updating various aspects of the filing, dependence on external vendors, and the general inefficiencies due to the Covid situation. Nevertheless, the Company is highly confident that the filings will occur in the…

    HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications.

    Unavoidable delays have been incurred in this project mainly due to the very long-term data, the standard requirements for updating various aspects of the filing, dependence on external vendors, and the general inefficiencies due to the Covid situation. Nevertheless, the Company is highly confident that the filings will occur in the near-term horizon, although this will likely be in first quarter, and not fourth quarter 2020.

    Dr Paul Averback, CEO said, "Fundamentally we are very pleased with the progress and the overall quality of the work going into our filings. We are as impatient as our shareholders but we are very confident that we will complete these important milestones in the near future. Our Fexapotide product is first in class, and has strong supportive long-term data. There is a large unmet need for a safe injectable with better efficacy than current medications and without the bothersome side effects of conventional drug treatments. The filings will occur as soon as possible but we cannot compromise on the quality for this ground-breaking treatment, and so we must ask again for patience from our valued supporters."

    Dr. Averback added, "We provide this update today to reassure our stakeholders that the Company is essentially on track and in the final stages of completing our NDA submission. The majority of the labor-intensive data updating and preparation for the chemistry, manufacturing and controls; the non-clinical scientific work, the safety studies, and the clinical modules have been accomplished. There remains some very important final writing steps to be completed, and we will continue to keep our shareholders up to date on the final stages of the filing documentation completion."

    The company also reported that Nymox management have personally invested USD $510,000 in direct placements in the Company's shares in the past 3 months.

    The Company further announced that an additional 9 international patents have been issued for FT for the treatment of BPH and prostate cancer since the last update, providing increasing coverage for the Company's lead product.

    Fexapotide (FT) has been designed and targeted for middle aged and elderly men throughout the world, who as they get older, develop enlarged prostate glands (BPH). Men with BPH often have progressive difficulties with urination and related symptoms that have serious impact upon their lives, causing discomfort, restricting activities, disrupting sleep, and leading to serious complications. With advancing age, a majority of men will have some degree of prostate enlargement, often with the resulting distressing urinary tract symptoms. Many men end up needing invasive surgery which can have long-term side effects such as permanent retrograde ejaculation and other risks.

    FT has shown long-term effectiveness for BPH without the distressing side effects often unavoidable with the available drugs and procedures. The results from the main U.S. multi-center randomized prospective blinded long-term studies of FT for BPH have been published in prestigious peer review journals including World Journal of Urology 2018 36: 801-809 (Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement authored by Neal Shore, Myrtle Beach, SC; Ronald Tutrone, Baltimore, MD; Mitchell Efros, Garden City, NY; Mohamed Bidair, San Diego, CA; Barton Wachs, Long Beach, CA; Susan Kalota, Tucson, AZ; Sheldon Freedman, Las Vegas, NV; James Bailen, Louisville, KY; Richard Levin, Towson, MD; Stephen Richardson, Salt Lake City, UT; Jed Kaminetsky, New York, NY; Jeffrey Snyder, Denver, CO; Barry Shepard, Garden City, NY; Kenneth Goldberg, Lewisville, TX); Alan Hay, Salem, OR; Steven Gange, Salt Lake City, UT; Ivan Grunberger, Brooklyn, NY (https ://doi.org/10.1007/s0034 5-018-2185-y)) and Therapeutic Advances in Urology 2019, Vol. 11: 1–16 (Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia authored by Neal Shore, Ronald Tutrone and Claus G. Roehrborn (https://journals.sagepub.com/doi/10.1177/1756287218820807)). Scientific studies were published recently in the highly regarded Research and Reports in Urology (2019 11:343-350) (https://doi.org/10.2147/RRU.S231334).

    FT has also shown effectiveness in slowing the progression of low grade early prostate cancer. Results from the large multi-center prospective long-term FT prostate cancer study were published in the peer review literature in the prestigious World Journal Of Urology 2020 in the report Prospective Evaluation of Fexapotide Triflutate Injection ‎Treatment of Grade Group 1 Prostate Cancer: Four Year Results authored by Neal Shore, Myrtle Beach, SC; Steven A. Kaplan, New York, NY; Ronald Tutrone, Baltimore, MD; Richard Levin, Towson, MD; James Bailen, Louisville, KY; Alan Hay, Salem, OR; Susan Kalota, Tucson, AZ; Mohamed Bidair, San Diego, CA; Sheldon Freedman, Las Vegas, NV; Kenneth Goldberg, Lewisville, TX; Frederick Snoy, Albuquerque, NM; Jonathan I. Epstein, Baltimore, MD. The FT prostate cancer article is available online at https://doi.org/10.1007/s00345-020-03127-w.

    The FT prostate cancer study enrolled 147 men with localized Gleason Grade 6 T1c prostate cancer at 28 U.S. clinical investigation sites. Patients were followed with clinical and laboratory evaluations and regular periodic prostate biopsies for up to 5 years. Important clinical highlights from the study include: FT treatment reduced cancer progression (-67.7%) compared to controls (3 years, FT 15mg, p<.02, pooled FT p=.0265) and also reduced (-54.7%) the incidence of surgery, radiotherapy or chemotherapy (4 years, FT 15mg p<.02; pooled FT p=.0374). At 4 years the incidence of surgery, radiotherapy or chemotherapy with increased Gleason grade was significantly reduced (FT 15mg -73.3% p=.0059, pooled FT p=.0064). Results for the high dose (FT 15mg) were superior to the lower dose (FT 2.5mg). Safety data showed no serious adverse events related to FT during the study.

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2019, and its Quarterly Reports.

    For Further Information Contact:

    Erik Danielsen        

    Nymox Pharmaceutical Corporation

    1-800-93NYMOX

    www.nymox.com



    Primary Logo

    View Full Article Hide Full Article
  6. HASBROUCK HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock at a purchase price of $2.50 per share in a registered direct offering for gross proceeds of approximately $9 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about August 14, 2020, subject to the satisfaction of customary closing conditions.

    Nymox intends to use the proceeds for general corporate purposes, including working capital.

    A.G.P./Alliance Global Partners is acting as sole placement agent for the offering…

    HASBROUCK HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock at a purchase price of $2.50 per share in a registered direct offering for gross proceeds of approximately $9 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about August 14, 2020, subject to the satisfaction of customary closing conditions.

    Nymox intends to use the proceeds for general corporate purposes, including working capital.

    A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

    This offering is being made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-237564) previously filed with the U.S. Securities and Exchange Commission (the "SEC"). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com. Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Nymox has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about Nymox and such offering.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2019, and its Quarterly Reports.

    For Further Information Contact:

    Erik Danielsen                                                                                                       

    Nymox Pharmaceutical Corporation

    1-800-93NYMOX

    www.nymox.com

    Primary Logo

    View Full Article Hide Full Article
  7. HASBROUCK HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report current updates on the Company's most important ongoing developments. The Company reports further significant and important progress has been made with remaining items for the upcoming regulatory filings in 2020 for the Company's first in class innovative prostate drug Fexapotide Triflutate (FT). The Company has moved swiftly ahead on its regulatory marketing applications by remote work with a strong team of expert collaborators, even with the occasional difficulties from the Covid situation leading to restricted or delayed access to certain required sources and to sites included in the Company's studies.

    Nymox is…

    HASBROUCK HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report current updates on the Company's most important ongoing developments. The Company reports further significant and important progress has been made with remaining items for the upcoming regulatory filings in 2020 for the Company's first in class innovative prostate drug Fexapotide Triflutate (FT). The Company has moved swiftly ahead on its regulatory marketing applications by remote work with a strong team of expert collaborators, even with the occasional difficulties from the Covid situation leading to restricted or delayed access to certain required sources and to sites included in the Company's studies.

    Nymox is also pleased to announce that it has recently formally filed with the regulatory authorities for new trademark brand names for FT in different jurisdictions including US and Europe. The Company will report further on these regulatory filings as they proceed.

    Nymox also announces that since its last communication, several FT-related patents have been newly granted based on applications filed in the recent past. FT has very strong global patent protection which translates into exclusivity rights in the major global markets.

    The Company will continue to provide regular updates on the progress in its regulatory filings which are expected in the near-term horizon.

    Fexapotide (FT) has been designed and targeted for middle aged and elderly men throughout the world, who as they get older, develop enlarged prostate glands (BPH). Men with BPH often have progressive difficulties with urination and related symptoms that have serious impact upon their lives, causing discomfort, restricting activities, disrupting sleep, and leading to serious complications. With advancing age, a majority of men will have some degree of prostate enlargement, often with the resulting distressing urinary tract symptoms. Many men end up needing invasive surgery which can have long-term side effects such as permanent retrograde ejaculation and other risks.

    FT has shown long-term effectiveness for BPH without the distressing side effects often unavoidable with the available drugs and procedures. The results from the main U.S. multi-center randomized prospective blinded long-term studies of FT for BPH have been published in prestigious peer review journals including World Journal of Urology 2018 36: 801-809 (Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement  authored by Neal Shore, Myrtle Beach, SC; Ronald Tutrone, Baltimore, MD; Mitchell Efros, Garden City, NY; Mohamed Bidair, San Diego, CA; Barton Wachs, Long Beach, CA; Susan Kalota, Tucson, AZ; Sheldon Freedman, Las Vegas, NV; James Bailen, Louisville, KY; Richard Levin, Towson, MD; Stephen Richardson, Salt Lake City, UT; Jed Kaminetsky, New York, NY; Jeffrey Snyder, Denver, CO; Barry Shepard, Garden City, NY; Kenneth Goldberg, Lewisville, TX); Alan Hay, Salem, OR; Steven Gange, Salt Lake City, UT; Ivan Grunberger, Brooklyn, NY (https ://doi.org/10.1007/s0034 5-018-2185-y)) and Therapeutic Advances in Urology 2019, Vol. 11: 1–16  (Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia authored by Neal Shore, Ronald Tutrone and Claus  G. Roehrborn  (https://journals.sagepub.com/doi/10.1177/1756287218820807)). Scientific studies were published recently in the highly regarded Research and Reports in Urology (2019 11:343-350) (https://doi.org/10.2147/RRU.S231334). 

    FT has also shown effectiveness in slowing the progression of low grade early prostate cancer. Results from the large multi-center prospective long-term FT prostate cancer study were published in the peer review literature in the prestigious World Journal Of Urology 2020 in the report Prospective Evaluation of Fexapotide Triflutate Injection ‎Treatment of Grade Group 1 Prostate Cancer: Four Year Results authored by Neal Shore, Myrtle Beach, SC; Steven A. Kaplan, New York, NY; Ronald Tutrone, Baltimore, MD; Richard Levin, Towson, MD; James Bailen, Louisville, KY; Alan Hay, Salem, OR; Susan Kalota, Tucson, AZ; Mohamed Bidair, San Diego, CA; Sheldon Freedman, Las Vegas, NV; Kenneth Goldberg, Lewisville, TX; Frederick Snoy, Albuquerque, NM; Jonathan I. Epstein, Baltimore, MD. The FT prostate cancer article is available online at https://doi.org/10.1007/s00345-020-03127-w.    

    The FT prostate cancer study enrolled 147 men with localized Gleason Grade 6 T1c prostate cancer at 28 U.S. clinical investigation sites. Patients were followed with clinical and laboratory evaluations and regular periodic prostate biopsies for up to 5 years.  Important clinical highlights from the study include: FT treatment reduced cancer progression (-67.7%) compared to controls (3 years, FT 15mg, p<.02, pooled FT p=.0265) and also reduced (-54.7%) the incidence of surgery, radiotherapy or chemotherapy (4 years, FT 15mg p<.02; pooled FT p=.0374). At 4 years the incidence of surgery, radiotherapy or chemotherapy with increased Gleason grade was significantly reduced (FT 15mg -73.3% p=.0059, pooled FT p=.0064). Results for the high dose (FT 15mg) were superior to the lower dose (FT 2.5mg). Safety data showed no serious adverse events related to FT during the study.

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2019, and its Quarterly Reports.

    For Further Information Contact:

    Erik Danielsen

    Nymox Pharmaceutical Corporation

    1-800-93NYMOX

    www.nymox.com

    Primary Logo

    View Full Article Hide Full Article
  8. HASBROUCK HEIGHTS, N.J., June 19, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of its regulatory documentation has proceeded very well, despite the inherent limitations of the business environment in 2020. Certain tasks have been hampered by the Covid pandemic restrictions, similar to other companies in the sector. These remaining tasks are expected to be completed reasonably soon as the Company regains the ability to retrieve required documentation from external sites and to complete other required tasks and on-site activities that were hindered due to the global…

    HASBROUCK HEIGHTS, N.J., June 19, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of its regulatory documentation has proceeded very well, despite the inherent limitations of the business environment in 2020. Certain tasks have been hampered by the Covid pandemic restrictions, similar to other companies in the sector. These remaining tasks are expected to be completed reasonably soon as the Company regains the ability to retrieve required documentation from external sites and to complete other required tasks and on-site activities that were hindered due to the global restrictions in place.

    Dr. Paul Averback, CEO commented "We are extremely pleased with the progress we have been able to achieve despite these obvious limitations due to the pandemic restrictions as we reported in our 6K filing on April 24. I want to thank the whole team for putting in an extraordinary effort towards meeting our regulatory timeline goals. Extremely complex tasks have been coordinated and executed successfully. Given the ongoing reopening of the economy we now expect to attend to the remaining matters near-term. Taking into account the above factors, we are well within our projected timelines as corrected for by the addition of the previously announced Covid-related delay of several months. We are now expecting to file our applications with the authorities approximately by the end of Q3 or early Q4. We will continue to regularly update our shareholders as we complete the entire packages."

    "Nymox management is very proud of the quality of our evidence and we not only look forward to the upcoming near-term submissions, but we are highly enthusiastic about the prospects for our Company and its shareholders. This is a field which has a substantial unmet medical need for safer and more effective treatments. The Company has achieved numerous major successes in the past couple years with its intellectual property applications around the world which have greatly extended the timeline value of the Company's Fexapotide treatments for prostate enlargement and for prostate cancer", Dr. Averback said.  

    For further in-depth detailed information about the Nymox treatments for prostate enlargement (BPH) and early stage prostate cancer please see peer review publications at the following links: https://doi.org/10.1007/s00345-018-2185-y and https://link.springer.com/article/10.1007/s00345-020-03127-w and visit www.nymox.com.

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2019, and its Quarterly Reports.

    For Further Information Contact:

    Erik Danielsen                                                                                                       

    Nymox Pharmaceutical Corporation

    1-800-93NYMOX

    www.nymox.com 

    Primary Logo

    View Full Article Hide Full Article
  9. HASBROUCK HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the recent allowances of 4 new different US and international patents concerning the Company's prostate enlargement and prostate cancer treatments. The new US and international patents that have been allowed are further expansions of Nymox's intellectual property covering the Company's prostate treatment technologies.

    Nymox CEO, Dr Paul Averback stated, "Intellectual property is one of the backbones of the biopharmaceutical industry. We are therefore very pleased to report that another 4 patents have recently been allowed. During the past year a total of 10 new patents have been allowed which adds to the Company's…

    HASBROUCK HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the recent allowances of 4 new different US and international patents concerning the Company's prostate enlargement and prostate cancer treatments. The new US and international patents that have been allowed are further expansions of Nymox's intellectual property covering the Company's prostate treatment technologies.

    Nymox CEO, Dr Paul Averback stated, "Intellectual property is one of the backbones of the biopharmaceutical industry. We are therefore very pleased to report that another 4 patents have recently been allowed. During the past year a total of 10 new patents have been allowed which adds to the Company's very strong intellectual property position for the future. Nymox continues with intensive work to maximize our IP portfolio for the long-term value and strength of the Company's proprietary foundations."

    Dr. Averback added, "Operationally at the present time, our employees are doing very well and are following the prescribed guidelines in their area, including working remotely, where necessary. On a different note, we are also extremely pleased with the reactions and feedback we are receiving from multiple sources with regard to the recent (Feb 2020) peer review journal article in the World Journal of Urology (https://link.springer.com/article/10.1007/s00345-020-03127-w) documenting the very promising clinical results of Fexapotide Triflutate in treating men with early prostate cancer. We look forward to advancing this program into pivotal registrational trials."

    The recent peer review publication is entitled "Prospective Evaluation of Fexapotide Triflutate Injection Treatment of Grade Group 1 Prostate Cancer: Four Year Results". The authors are Neal Shore, Myrtle Beach, SC; Steven A. Kaplan, New York, NY; Ronald Tutrone, Baltimore, MD; Richard Levin, Towson, MD; James Bailen, Louisville, KY; Alan Hay, Salem, OR; Susan Kalota, Tucson, AZ; Mohamed Bidair, San Diego, CA; Sheldon Freedman, Las Vegas, NV; Kenneth Goldberg, Lewisville, TX; Frederick Snoy, Albuquerque, NM; Jonathan I. Epstein, Baltimore, MD.

    The Fexapotide (FT) prostate cancer study was started in 2012 and enrolled 147 men with localized Gleason Grade 6 T1c prostate cancer at 28 U.S. clinical investigation sites. Patients were followed with clinical and laboratory evaluations and regular periodic prostate biopsies for up to 5 years. Patients randomized to FT were treated with a single one-time targeted injection of FT, either 2.5mg or 15mg. Statistical comparisons were made over time of the proportions of subjects and untreated controls who progressed to higher Gleason grade and/or invasive treatments instituted with prostatectomy, radiotherapy, or chemotherapy. Important clinical highlights from the study include:

    • FT treatment reduced cancer progression (-67.7%) compared to controls (3 years, FT 15mg, p<.02, pooled FT p=.0265).
    • FT treatment group had reduced (-54.7%) incidence of surgery, radiotherapy or chemotherapy (4 years, FT 15mg p<.02; pooled FT p=.0374).
    • At 4 years the incidence of surgery, radiotherapy or chemotherapy with increased Gleason grade was significantly reduced (FT 15mg -73.3% p=.0059, pooled FT p=.0064).
    • Results for the high dose (FT 15mg) were superior to the lower dose (FT 2.5mg). Safety data showed no serious adverse events related to FT during the study.

    FT is a pro-apoptotic proprietary drug which promotes natural programmed cell death (apoptosis) in prostatic glandular cells which compose the prostate cancer. FT has been safely administered to men in clinical trials in the U.S. involving over 1700 patients and controls treated for BPH or prostate cancer. FT has completed Phase 3 studies for BPH and further studies of FT for prostate cancer are planned in the near future.

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2019, and its Quarterly Reports.

    For Further Information Contact:
    Erik Danielsen
    Nymox Pharmaceutical Corporation
    1-800-93NYMOX
    www.nymox.com

    Primary Logo

    View Full Article Hide Full Article
  10. HASBROUCK HEIGHTS, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer.

    This report represents the first publication in the medical literature of multi-year long-term data from a well-powered prospective randomized multi-center clinical trial for a prostate injectable treatment in men targeted to low grade early prostate cancer and showing statistically significant efficacy for a locally targeted molecular injectable treatment.

    The new publication is entitled "Prospective Evaluation…

    HASBROUCK HEIGHTS, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer.

    This report represents the first publication in the medical literature of multi-year long-term data from a well-powered prospective randomized multi-center clinical trial for a prostate injectable treatment in men targeted to low grade early prostate cancer and showing statistically significant efficacy for a locally targeted molecular injectable treatment.

    The new publication is entitled "Prospective Evaluation of Fexapotide Triflutate Injection ‎Treatment of Grade Group 1 Prostate Cancer: Four Year Results". The authors are Neal Shore, Myrtle Beach, SC; Steven A. Kaplan, New York, NY; Ronald Tutrone, Baltimore, MD; Richard Levin, Towson, MD; James Bailen, Louisville, KY; Alan Hay, Salem, OR; Susan Kalota, Tucson, AZ; Mohamed Bidair, San Diego, CA; Sheldon Freedman, Las Vegas, NV; Kenneth Goldberg, Lewisville, TX; Frederick Snoy, Albuquerque, NM; Jonathan I. Epstein, Baltimore, MD. The article is available online at https://link.springer.com/article/10.1007/s00345-020-03127-w.     

    The Fexapotide (FT) study was started in 2012 and enrolled 147 men with localized Gleason Grade 6 T1c prostate cancer at 28 U.S. clinical investigation sites. Patients were followed with clinical and laboratory evaluations and regular periodic prostate biopsies for up to 5 years. Patients randomized to FT were treated with a single one-time targeted injection of FT, either 2.5mg or 15mg. Statistical comparisons were made over time of the proportions of subjects and untreated controls who progressed to higher Gleason grade and/or invasive treatments instituted with prostatectomy, radiotherapy, or chemotherapy. Important clinical highlights from the study include: FT treatment reduced cancer progression (-67.7%) compared to controls (3 years, FT 15mg, p<.02, pooled FT p=.0265) and also reduced (-54.7%) the incidence of surgery, radiotherapy or chemotherapy (4 years, FT 15mg p<.02; pooled FT p=.0374). At 4 years the incidence of surgery, radiotherapy or chemotherapy with increased Gleason grade was significantly reduced (FT 15mg -73.3% p=.0059, pooled FT p=.0064). Results for the high dose (FT 15mg) were superior to the lower dose (FT 2.5mg). Safety data showed no serious adverse events related to FT during the study.

    The current recommended standard of care for these patients is active surveillance: patients are monitored carefully over time to determine if and when the cancer becomes more advanced and thus will require more aggressive treatment, like radiation therapy or surgery.

    Dr. Neal Shore, lead author of the report, said "The study results demonstrate data in a large multi-center clinical trial of men treated with transrectal ultrasound guided FT for early stage, low risk prostate cancers, which suggest an effective result for reducing histopathologic progression, as evidenced by repeated biopsies over time, while also demonstrating a favorable safety profile. This study presents long-term FT data which supports its efficacy for avoidance of biologic progression in an active surveillance prostate cancer population. A therapy to optimize the success of an active surveillance strategy is a welcomed advance for these patients."

    Dr Steven Kaplan, Professor of Urology and Director of the Benign Urologic Diseases and The Men's Health Program at Icahn School of Medicine at Mount Sinai, New York, and a co-author of the report said, "This study reports the long-term data from a prospective study of an injectable for localized Grade Group 1 prostate cancer -- which is the first time this has been accomplished for a very common problem in men. Regulatory approval of Fexapotide Triflutate (FT) will be a very important treatment adjunct for countless men with this problem."

    The FT treatments were administered in a urology office setting without anesthesia or sedation, consisting of a single relatively painless transrectal injection into the area of the prostate cancer. The percentage of patients with surgery or radiotherapy with Gleason grade progression was reduced by 73.3% in patients treated with a single injection of FT 15mg and by 62.6% in pooled (high and low dose FT groups combined) FT patients compared to controls.

    Dr. Jonathan Epstein a co-author and researcher involved in the study, stated "Although more and more men are electing active surveillance for low grade prostate cancer, approximately 25-35% will show increased grade on follow-up biopsy which typically leads to definitive therapy. In this study, Fexapotide Triflutate decreased the risk of upgrading on follow-up biopsy enabling men to stay on active surveillance. Even if Fexapotide Triflutate enables men to stay on active surveillance longer before they eventually experience upgrading, there would be a significant benefit for men to delay the onset of side effects associated with therapy and in the interim enjoy a better quality of life. Future studies are needed to expand the criteria for study of Fexapotide Triflutate to include men with large volume Grade Group 1 disease and possibly men with low volume, low percent pattern 4 Grade Group 2 cancer. Identifying the ideal candidates for Fexapotide Triflutate also factoring in multiparametric MRI findings remains to be determined."

    FT is a pro-apoptotic proprietary drug which promotes natural programmed cell death (apoptosis) in prostatic glandular cells which compose the prostate cancer. FT has been safely administered to men in clinical trials in the U.S. involving over 1700 patients and controls treated for BPH or prostate cancer. FT has completed Phase 3 studies for BPH and further studies of FT for prostate cancer are planned in the near future.

    For further detailed information about the published study please refer to the new report online at the World Journal of Urology.

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018, and its Quarterly Reports.

    For Further Information Contact:
    Erik Danielsen
    Nymox Pharmaceutical Corporation
    1-800-93NYMOX
    www.nymox.com

     

    Primary Logo

    View Full Article Hide Full Article
  11. HASBROUCK HEIGHTS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs.  Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries.

    Dr. Thomson is a Fellow of the Royal Society of Chemistry (UK), a Chartered Chemist and Chairman of the Royal Society of Chemistry Qualified Persons Assessors Panel.  He has worked in the pharmaceutical industry in positions including Head of Quality and Director of QA and Regulatory Affairs, and as Consultant Qualified Person at numerous large and small drug manufacturing…

    HASBROUCK HEIGHTS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs.  Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries.

    Dr. Thomson is a Fellow of the Royal Society of Chemistry (UK), a Chartered Chemist and Chairman of the Royal Society of Chemistry Qualified Persons Assessors Panel.  He has worked in the pharmaceutical industry in positions including Head of Quality and Director of QA and Regulatory Affairs, and as Consultant Qualified Person at numerous large and small drug manufacturing facilities in the EU and the US for over 20 years.  Dr. Thomson was a Chartered Scientist with The Science Council (UK) from 2004-2010 and Corporate Member of the South African Chemical Institute from 1980-1999. He received his PhD in Chemistry from the University of South Africa.

    Dr. Paul Averback, CEO of Nymox said, "Management and the Board are extremely pleased to have Dr. Thomson take on the position of VP of Quality and Regulatory Affairs. This is a key management position at a crucial time in the Company's history as we are soon to submit both an NDA in the U.S. and an MAA in Europe. Dr. Thomson will work closely with Dr. Mark Staples, Nymox VP for Chemistry Manufacturing and Controls, to jointly assure that Nymox's manufacturing standards are fully compliant with all US and international regulations. As VP of Quality and Regulatory Affairs, Dr. Thomson is responsible for all activities related to Quality Control and Quality Assurance of Nymox's manufacturing in the US and the EU. Russell is an authority on implementation of Quality Assurance for manufacturing in this sector and brings to Nymox his vast knowledge and practical experience. His appointment to VP of Quality and Regulatory affairs is great news for the Nymox team and our collaborators."

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018, and its Quarterly Reports.

    For Further Information Contact:

    Erik Danielsen
    Nymox Pharmaceutical Corporation
    1-800-93NYMOX
    www.nymox.com

     

    Primary Logo

    View Full Article Hide Full Article
  12. HASBROUCK HEIGHTS, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to provide a current January 2020 update on several important corporate activities and achievements since the last update in October 2019.

    The Company recently received the necessary information regarding the formatting and content of its upcoming regulatory filings for its Fexapotide Triflutate (FT) first in class injectable drug to treat the symptoms of prostate enlargement (BPH) in men. The Company is proceeding to integrate safety data from its four Phase I and Phase II BPH clinical trials as well as the safety data from Prostate Cancer Study NX03-0040 into the final dataset (that also includes 4 Phase 3 trials) that will…

    HASBROUCK HEIGHTS, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to provide a current January 2020 update on several important corporate activities and achievements since the last update in October 2019.

    The Company recently received the necessary information regarding the formatting and content of its upcoming regulatory filings for its Fexapotide Triflutate (FT) first in class injectable drug to treat the symptoms of prostate enlargement (BPH) in men. The Company is proceeding to integrate safety data from its four Phase I and Phase II BPH clinical trials as well as the safety data from Prostate Cancer Study NX03-0040 into the final dataset (that also includes 4 Phase 3 trials) that will be part of the New Drug Application (NDA) submission. The filings seeking approvals in the US and in Europe are now targeted for the first half of 2020 in both jurisdictions. At this point, the Company does not have any barriers to report and does not expect any delays.

    Nymox is further pleased to report that another peer review publication (as anticipated in the Company's October 21, 2019 Press Release) was recently accepted and published in Research and Reports in Urology. This publication discusses the selective cellular ablation capabilities of Fexapotide Triflutate to induce apoptosis (natural cell death) in prostate glandular cells which are a major part of the prostate enlargement which defines benign prostatic hyperplasia. Selective pharmaco-ablation is achieved while leaving the nerve cells and urethra and other nearby tissues (all crucial for normal sexual function) unaffected. In fact, the Company has previously reported a statistically significant improvement in sexual function reported by men treated with FT for BPH in its U.S. Phase III long-term follow up studies.

    A fourth new and important peer review article is expected to appear in the near term. Further information will be provided when the new article appears.

    Dr Paul Averback, CEO commented, "We are very pleased to provide these positive substantiated updates to shareholders today. Now, after many months of intensive work with our regulatory advisors and experts, we are confident that we have the needed clarity concerning the optimal formatting and content protocols being undertaken. The Company is currently highly focused on expeditiously completing the final legs of its regulatory pre-filing responsibilities."

    The new peer review article reported in January 2020 and published in Research and Reports in Urology provided detailed documentation of the selective pharmco-ablation mechanism of action of FT, demonstrating the highly selective reduction of prostate cells which comprises one of the most important underlying reasons for the highly superior safety and efficacy of Fexapotide.

    According to the new paper, "a traditional major challenge for treatment has been to promote or to directly produce tissue destruction that is structurally selective at the microscopic (histological) level, in order to avoid undesirable toxicities and irreparable damage to key adjacent structures. For example, transurethral resection, high energy laser extirpations and other methods may damage prostatic nerves and peri-urethral musculature, with the consequent occurrences of ejaculatory disorders, sexual dysfunction and /or incontinence."

    The article further states, "this is the first demonstration of a molecular treatment that can produce structurally significant and focally targeted destruction of prostate epithelial gland growth combined with complete or near complete preservation of key nerves and structural elements in intimate structural proximity to the foci of ablation."

    A review article on the progress in the development of Fexapotide entitled "Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia" authored by Neal Shore, MD, FACS (Carolina Urologic Research Center, Myrtle Beach, SC); Ronald Tutrone, MD, FACS (Chesapeake Urology Research Associates, Baltimore, MD); and Claus G. Roehrborn, MD (University of Texas Southwestern Medical Center, Dallas, TX) was published in Therapeutic Advances in Urology. 2019;11:1-16.

    The clinical trial results for Fexapotide treatment of BPH are published in the World Journal of Urology May 2018, Volume 36, pages 801–809 (https://doi.org/10.1007/s00345-018-2185-y) in a peer review report entitled "Fexapotide Triflutate: Results of Long- Term Safety and Efficacy Trials of a Novel Injectable Therapy for Symptomatic Prostate Enlargement" authored by Neal Shore, MD, FACS (Carolina Urologic Research Center, Myrtle Beach, SC); Ronald Tutrone, MD, FACS (Chesapeake Urology Research Associates, Baltimore, MD); Mitchell Efros, MD, FACS (Accumed Research, Garden City, NY); Mohamed Bidair, MD (San Diego Clinical Trials, San Diego, CA); Barton Wachs, MD (Atlantic Urology Medical Group, Long Beach, CA); Susan Kalota, MD (Urological Associates of Southern Arizona, Tucson, AZ); Sheldon Freedman, MD, FACS (Freedman Urology, Las Vegas, NV); James Bailen, MD, FACS (First Urology, Louisville, KY); Richard Levin, MD, FACS (Chesapeake Urology Research Associates, Towson, MD); Stephen Richardson, MD (Jean Brown Research, Salt Lake City, UT); Jed Kaminetsky, MD, FACS (University Urology, New York, NY); Jeffrey Snyder, MD, FACS (Genitourinary Surgical Consultants, Denver, CO); Barry Shepard, MD, FACS (Urological Surgeons of Long Island, Garden City, NY); Kenneth Goldberg, MD, FACS (U T Southwestern Dept of Urology, Lewisville, TX); Alan Hay, MD, FACS (Willamette Urology, Salem, OR); Steven Gange, MD, FACS (Summit Urology Group, Salt Lake City, UT); Ivan Grunberger, MD, FACS (Brooklyn Urology, Brooklyn, NY).

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018, and its Quarterly Reports.

    For Further Information Contact:
    Erik Danielsen                                                                                                       
    Nymox Pharmaceutical Corporation
    1-800-93NYMOX
    www.nymox.com

    Primary Logo

    View Full Article Hide Full Article
  13. HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report a new peer review research report has been published on experimental studies of the Company's Fexapotide Triflutate treatment for prostate enlargement (BPH) and low grade prostate cancer. The article is entitled "Fexapotide triflutate induces selective prostate glandular pharmaco-ablation in the rat" and it is published in Research and Reports in Urology.

    The research report presents data and scientific evidence for how Fexapotide inhibits prostate enlargement by selectively eliminating prostate glandular cells while preserving key elements including nerves, blood vessels, and adjacent structures. This exquisitely…

    HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report a new peer review research report has been published on experimental studies of the Company's Fexapotide Triflutate treatment for prostate enlargement (BPH) and low grade prostate cancer. The article is entitled "Fexapotide triflutate induces selective prostate glandular pharmaco-ablation in the rat" and it is published in Research and Reports in Urology.

    The research report presents data and scientific evidence for how Fexapotide inhibits prostate enlargement by selectively eliminating prostate glandular cells while preserving key elements including nerves, blood vessels, and adjacent structures. This exquisitely selective ablation mechanism is one of several main reasons that Fexapotide has achieved its excellent safety profile in human trials involving over 1700 injections of Fexapotide and controls. Research and Reports in Urology is a very highly respected international peer review journal of urological research. The full peer review article is available online at https://doi.org/10.2147/RRU.S231334

    According to the article, "These studies in the rat have shown that FT intraprostatic administration consistently leads to significant and selective prostate glandular epithelial apoptotic cell loss and gland shrinkage, with the absence of discernible damage to adjacent and surrounding tissues including nerves, blood vessels and other important structures. Gland-specific targeted molecular ablation of overgrown prostatic glands in the transition zone in the prostate with nerve sparing is a novel mechanism of action for a prostate therapeutic which has important benefits. The nerve and stromal sparing for peri-prostatic tissues provides an objective underlying basis for the observed safety of FT treatment in human BPH studies."

    The report concludes, "A major challenge for prostate treatments has been to produce or promote beneficial targeted gland destruction that is structurally selective at the microscopic tissue level in order to avoid undesirable toxicities and irreparable damage to important adjacent structures. Fexapotide triflutate (FT) has been shown in human clinical trials to be a well-tolerated pharmaco-ablative agent with therapeutic benefit in patients with prostate enlargement and low-grade prostate cancer. Evidence from experimental animal studies shows that FT leads to prostate glandular cell loss not found in controls, by apoptosis that is highly selective with sparing of nerves, vascular elements and stroma, and near-total loss of glandular epithelium at 12 months."

    The new report was authored by Paul Averback, MD; Rajna Gohal, M.Sc, Marta Fuska, Kathleen Prins, and Ping Wang, MD.

    Nymox's lead drug Fexapotide (FT) has been in development for over 10 years and has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, and has been found after 7 years of prospective placebo controlled double blind studies of treatment of 977 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. FT has been shown to produce long-term improvements in lower urinary tract symptoms associated with prostate enlargement (BPH), a problem that afflicts an estimated 100 million or more men in the world. FT does not cause the annoying side effects and risks found with available treatments for BPH. FT is also in development for low grade prostate cancer.

    A review article on the progress in the development of Fexapotide entitled "Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia" authored by Neal Shore, MD, FACS (Carolina Urologic Research Center, Myrtle Beach, SC); Ronald Tutrone, MD, FACS (Chesapeake Urology Research Associates, Baltimore, MD); and Claus G. Roehrborn, MD (University of Texas Southwestern Medical Center, Dallas, TX) was published in Therapeutic Advances in Urology. 2019;11:1-16.

    The clinical trial results for Fexapotide treatment of BPH are published in the World Journal of Urology May 2018, Volume 36, pages 801–809 (https://doi.org/10.1007/s00345-018-2185-y) in a peer review report entitled "Fexapotide Triflutate: Results of Long- Term Safety and Efficacy Trials of a Novel Injectable Therapy for Symptomatic Prostate Enlargement" authored by Neal Shore, MD, FACS (Carolina Urologic Research Center, Myrtle Beach, SC); Ronald Tutrone, MD, FACS (Chesapeake Urology Research Associates, Baltimore, MD); Mitchell Efros, MD, FACS (Accumed Research, Garden City, NY); Mohamed Bidair, MD (San Diego Clinical Trials, San Diego, CA); Barton Wachs, MD (Atlantic Urology Medical Group, Long Beach, CA); Susan Kalota, MD (Urological Associates of Southern Arizona, Tucson, AZ); Sheldon Freedman, MD, FACS (Freedman Urology, Las Vegas, NV); James Bailen, MD, FACS (First Urology, Louisville, KY); Richard Levin, MD, FACS (Chesapeake Urology Research Associates, Towson, MD); Stephen Richardson, MD (Jean Brown Research, Salt Lake City, UT); Jed Kaminetsky, MD, FACS (University Urology, New York, NY); Jeffrey Snyder, MD, FACS (Genitourinary Surgical Consultants, Denver, CO); Barry Shepard, MD, FACS (Urological Surgeons of Long Island, Garden City, NY); Kenneth Goldberg, MD, FACS (U T Southwestern Dept of Urology, Lewisville, TX); Alan Hay, MD, FACS (Willamette Urology, Salem, OR); Steven Gange, MD, FACS (Summit Urology Group, Salt Lake City, UT); Ivan Grunberger, MD, FACS (Brooklyn Urology, Brooklyn, NY).

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018, and its Quarterly Reports.

    For Further Information Contact:
    Erik Danielsen
    Nymox Pharmaceutical Corporation
    1-800-93NYMOX
    www.nymox.com

    Primary Logo

    View Full Article Hide Full Article
  14. HASBROUCK HEIGHTS, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United States, European, and other jurisdictional formal patent issuances covering Fexapotide Triflutate and its use for prostate and urinary tract disorders. The effective coverage for the treatments has now been extended to 18 years into 2037 and later in the major global regions. These new patents are fully assigned to the Corporation and are the property of Nymox shareholders.

    Dr. Paul Averback CEO of Nymox commented, "Our team has been working diligently for many years and these intellectual property extensions are some of the…

    HASBROUCK HEIGHTS, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United States, European, and other jurisdictional formal patent issuances covering Fexapotide Triflutate and its use for prostate and urinary tract disorders. The effective coverage for the treatments has now been extended to 18 years into 2037 and later in the major global regions. These new patents are fully assigned to the Corporation and are the property of Nymox shareholders.

    Dr. Paul Averback CEO of Nymox commented, "Our team has been working diligently for many years and these intellectual property extensions are some of the fruits of our labors. For our shareholders this effectively is a major increase in the conventionally recognized timeline of proprietary rights, and thus the market exclusivity of our products and long-term valuations if approved. It is work that requires persistence, but good things normally take their time to be done properly. The best quality companies plan for and execute long-term. Nymox has strong shareholders who have provided our team with the patient support and capital needed to make these important advances."

    Nymox also reported today that its efforts involved in the upcoming filings for approval for Fexapotide in the US and in Europe have steadily been moving forward. The Company had its pre-filing Chemistry Manufacturing and Controls meeting with FDA in April 2019 which was successful. The Company is currently preparing to seek similar formal clarification from the authorities on data formatting and standardization for the filings which is a necessary step and which it expects to receive in the near future. After the latter, the Company expects to be able to report to shareholders with further precision about expected timelines for the two filings. Because the data involved in the program has extended over a very long time period (which is a positive), it has also generated additional requirements of data formatting updates and other specific procedures for the filings.

    Management continues to work extremely hard and diligently towards completing the preparatory work necessary for submitting the applications for marketing approval both in the US (NDA) and in Europe (MAA). Significant time and efforts – working with external expert teams – has been put into the extremely important critical tasks involved in bringing all aspects of the applications current with all the required regulations and requirements in the two different applications.  Amongst others, these additional efforts by the teams have included intensive work in the areas of updated computer coding of databases, updated formatting of data and required terminologies for drug effects and longer-term effects, shelf-life documentation, auditing documentation, quality assurance and control systems, and a variety of other updating activities needed to fully comply with all the current regulations.  

    Dr. Averback said, "We reiterate to our shareholders that the Company has engaged several outside contractor groups with extensive relevant experience and established expertise. These experts are actively and collectively managing key aspects of our preparatory regulatory work. With $9.1M in the bank last quarter, we have the necessary financial resources to complete the preparatory work for filing our two current marketing applications in Europe and US, and also to complete the required procedures during the regulatory review processes for the first two applications. Management is completely focused towards assuring that when our regulatory submissions are made, the Company will have done everything conceivable to achieve the highest quality standards for our submissions, which we strongly believe is in the very best interest of all shareholders of Nymox."

    Nymox is further pleased to report that two new peer review manuscripts concerning the Fexapotide investigations have recently been prepared and which are in the process of being submitted for publication. The Company looks forward to reporting further on these and other exciting developments in the near future at the appropriate time.

    In addition to many well-received presentations of Fexapotide data and clinical trial results at American Urological Association meetings and other public forums in the field in the past two years, there have been two prestigious publications of extensive data and results of Fexapotide studies published in the peer-review medical literature. The first in 2018 was "Fexapotide triflutate: results of long term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement". World Journal of Urology 2018;36(5):801-9 authored by Drs N. Shore, R. Tutrone, M. Efros, M. Bidair, B. Wachs, S. Kalota, S. Freedman, J. Bailen, R. Levin, S. Richardson, J. Kaminetsky, J. Snyder, B. Shepard, K. Goldberg, A. Hay, S. Gange, and I. Grunberger. The second in 2019 was "Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia". Therapeutic Advances in Urology. 2019;11:1-16." authored by Drs N. Shore, R. Tutrone, and C. Roehrborn.

    For more information please contact info@nymox.com or 800-936-9669.

    Forward Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018, and its Quarterly Reports.

    For Further Information Contact:
    Erik Danielsen
    Nymox Pharmaceutical Corporation
    1-800-93NYMOX
    www.nymox.com

    Primary Logo

    View Full Article Hide Full Article